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1. Introduction
  It is estimated that about 1 billion people in Asia and 
Pacific region are infected with tuberculosis, of whom 
presently about 2.5 million are also infected with HIV[1]. 
Hospital based HIV seroprevalence studies amongst 
tuberculosis patients from different regions of India 
have shown a great variation in prevalence[2]. HIV 
infection is considered as potent risk factor for fueling 
progression to active tuberculosis in people already 
infected with Mycobacterium tuberculosis. Though 
there has been global scale up of rapid HIV testing on 
blood with encouraging uptake, even in tuberculosis 
patients, it has to be kept in mind that TB diagnosis and 
treatment are often performed entirely on an out-patient 
basis and require no blood testing. In such a setting, and in 
view of the low endemicity of HIV in our area, we felt that 
we could utilize the ease of availability of sputum samples 
in tuberculosis patients to screen for the presence of TB/
HIV coinfection in sputum samples without an immediate 
need for collection of blood samples. We hypothesized that 
such a screening test might help increase uptake of testing, 
since there is no blood collection involved. Currently, there 
is cross referral of TB suspects and patients to the National 
AIDS Control Programme, from the Revised National TB 
Control Programme, for a blood test to detect HIV infection. 
This may lead drop out of patients during the referral 
process, particularly given the stigma associated with HIV 
infection. This is a major cause for concern in the attempts 
to carry out routine HIV testing in this population. In such 
cohorts, simple, non-invasive, rapid, point of care tests for 
HIV on easily available clinical samples have the potential 
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to overcome these issues, and to add to the strength of 
existing HIV screening programs.
  The OraQuick® HIV-1/2 Assay (OraSure Technologies, 
Inc., Bethlehem, PA, USA) is a visually-read qualitative 
immunochromatographic test for the detection of antibodies 
to HIV-1 and -2 in gingival secretions and blood. Its 
availability for use on sputum would reduce health care 
worker exposure to blood and be useful for HIV surveillance 
among TB suspects. The purpose of this study was to 
determine whether the OraQuick HIV-1/2 Assay in sputum 
is a valid tool for HIV surveillance among TB patients.
2. Material and methods
  A cross sectional study was conducted between May 2008 
and October 2008 at our hospital and the local TB Hospital. 
The project was approved by the Institutional Review Board 
of our institute. 
2.1. Inclusion and exclusion criteria
  Adult participants with fever, chronic cough of more than 
3 week duration with or without haemoptysis, loss of weight 
and history suggestive of high risk behaviour (ie., multiple 
sexual partners, intravenous drug usage, occupations like 
long distance truck driving), who were suspected to be 
TB/HIV co-infected, were included in the study. Such 
patients had sputum smear examination for acid fast 
bacilli and sputum culture for mycobacteria carried out 
as a part of their diagnostic work up. Patients with sputa 
smear positive for acid fast bacilli and/or culture positive 
for mycobacteria were also included in the study. Patients 
requiring life support, or with psychiatric illnesses (from 
whom a valid consent could not be obtained) were excluded. 
317 participants fulfilled the inclusion criteria and were 
included in the study.
2.2. Collection of samples, and assessment of client preference
  After informed consent, participants underwent pre 
test counseling followed by post test counseling, as per 
guidelines of the National AIDS Control Organization, India. 
Their sputum samples were collected. HIV antibody testing 
was conducted on the collected sputum specimens using 
OraQuick® HIV-1/2 Assay (OraSure Technologies, Inc., 
Bethlehem, PA, USA). Blood samples collected for testing of 
HIV antigen and antibody by ELISA. In patients who gave 
consent for collection of an extra 10 mL of blood, blood was 
collected for detection of HIV by PCR. The preference of 
participants for Oraquick testing was assessed by a face-to-
face interview. 
2.3. Lab procedures
  HIV testing was performed according to the method used 
in an earlier study[3] using OraQuick® HIV-1/2 Assay. 
OraQuick® HIV-1/2 Assay is a visually read qualitative 
immunochromatographic test for the detection of antibodies 
to HIV-1 and -2. The porous flat pad of the QraQuick device 
was stirred in the sputum specimen for at least 60 s, placed 
in the developer vial and read after 20 to 60 min. If the 
control line was visible, the test was interpreted. An HIV-
non reactive result was one that showed a single positive 
control line, and an HIV-reactive result was one that showed 
two lines: a line for the positive control and a line for the test 
sample. 
  The OraQuick® HIV-1/2 Assay results were confirmed 
by using two ELISAs on serum, Anti-HIV TETRA ELISA 
(Biotest, Landsteinerstr.5, D-63303 Dreieich, Germany), 
GENSCREEN® PLUS HIV Ag-Ab (BIO-RAD 3, Bd Raymond 
Poincare, 92430 MARNES LA COQUETTE, France).  
  In this study, we chose two ELISAs as reference standard, 
and reconfirmed with a third ELISA (4th Generation Microlisa 
HIV Ag & Ab, J.Mitra & Co. Pvt. Ltd., New Delhi, India). We 
provided risk reduction counseling and asked the patients to 
return after 3 months, should they suspect exposure.
2.4. PCR
  PCR for HIV was performed on blood samples from the 102 
patients who gave consent for collection of an extra 10 mL
blood for the PCR test using COBAS AMPLICOR HIV-1 
monitor test version 1.5 kit (Roche Diagnostic Systems, 
Branchhburg, NJ, USA). The tests were carried according to 
the manufacturer’s guidelines.
2.5. Data analysis
  Using the three serum ELISAs as a gold standard, 
Abramson, J. H. WINPEPI (PEPI-for-Windows) was used to 
determine sensitivity, specificity and confidence intervals.
3. Results
3.1. Description of the study population
  The study sample included 317 participants. The median 
age was 38 years (range 14-77). Of 317 participants, 
235(74.13%) were male. According to the categories of 
treatment as defined by the Revised National Tuberculosis 
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Control Program (RNTCP) of India (RNTCP at a glance), 174 
participants (54.88%) belonged to category-栺, 138(43.53%) 
belonged to category-栻 and five (1.57%) belonged to 
category-栿. 
3.2. Diagnostic accuracy of OraQuick tests
  Compared to serum ELISA for HIV, the OraQuick® HIV-1/2 
Assay in sputum specimens reported 90% sensitivity (9/10) 
and 100% specificity (307/307), with a positive predictive 
value of 100% and a negative predictive value of 99.68% 
(Tables 1&2).
Table 1
Comparison of results of serum ELISA for HIV and OraQuick® HIV-
1/2 assay in sputum.
Results of serum ELISA
Results of Oraquick assay on sputum
Total
Positive Negative
Reactive 9     1   10
Nonreactive 0 307 307
Total 9 308 317
Table 2
Performance characteristics of OraQuick® HIV-1/2 assay in sputum.
Performance Value in % (95% CI)
Sensitivity   90.00 (55.50-99.75)
Specificity 100.00 (98.81-100.00)
Positive predictive value 100.00 (66.37-100.00)
Negative predictive value   99.68 (98.20-99.99)
3.3. Results of PCR for HIV
  Of the 102 samples tested for HIV by PCR, there was 
concordance between PCR, triple ELISAs on serum and 
OraQuick on sputum in 95 samples. Six samples were 
negative by triple ELISAs and by OraQuick on sputum and 
serum, but were reactive by PCR. One sample was non 
reactive by PCR and by OraQuick on sputum and serum but 
positive by triple ELISAs.
3.4. Client preference for HIV testing modalities
  The OraQuick® HIV-1/2 Assay on sputum was preferred 
by 65% of the participants over ELISA. Of 317 participants, 
111(35%) reported discomfort, at the time of blood sample 
collection for ELISA, and for PCR. Preference was defined as 
an unequivocal choice of one test modality over another.
3.5. Prevalence of HIV infection using reference standard
  Of 317 participants tested for sputum by OraQuick® HIV-
1/2 Assay, nine were reactive, and confirmed by dual 
ELISAs. Of the nine co-infected patients, five belonged 
to category-I and four to category-II. Prevalence of HIV 
infection was 3.15%, with 95% CI 1.52%-5.72%. 
4. Discussion
  Due to the increasing availability of interventions for 
HIV-infected persons in resource-poor settings, the 
ideal situation is to have all patients accept HIV testing 
in order to prevent HIV transmission and to access care 
programs. Detection of HIV in TB cases is the first step 
towards bringing patients that are co-infected into care and 
prevention. Currently, the RNTCP[4] accepts cross referral 
of patients between DOTs centres and Integrated Couselling 
and Testing Centres for detection of HIV infection.
  In our study, in patients with tuberculosis, only 10 samples 
were HIV positive. This is probably because of the low HIV 
prevalence in our area. Significant parts of our country 
have low HIV prevalence, and this study would be relevant 
especially in such areas. In this study, Oraquick was found 
have 90% sensitivity and 100% specificity in sputum, with a 
positive predictive value of 100% and a negative predictive 
value of 99.68%.  
  Additionally, client preferences were definitely higher 
(65%) for OraQuick® HIV-1/2 Assay on sputum rather than 
a test involving collection of a blood sample (35%). This 
was, in a large part, due to the fact that it is a non invasive 
test. With a positive predictive value of 100% in an area of 
low endemicity for HIV, and higher client preferences, the 
test may have utility in screening for coinfection in sputum 
samples in TB cases and suspects. In the current scenario, it 
certainly cannot replace a blood test, but may help prevent 
loss to follow up of patients cross referred between the TB 
and AIDS control programmes. This, in itself will help boost 
detection rates of patients coinfected with TB and HIV. 
  TB/HIV co-infection was detected in 5 category-栺 and 4 
category-栻 patients. Given that there were only 5 category-
栿 patients who were included in the study. It is difficult to 
ascertain the significance of the apparently higher incidence 
of TB/HIV co-infection in category-栺 and category-栻 
patients.
  In 6 patients, HIV infection was detected by PCR but not 
but by ELISA on serum or OraQuick on sputum. This could 
be explained by the fact that PCR can pick up viral nucleic 
acid which appears much earlier in the course of the disease 
than viral antibodies and antigen, unless infection is caused 
by transfusion of infected blood. In one patient, however 
antibodies were detected by ELISA, but not by OraQuick 
on serum or sputum, probably due to the higher sensitivity 
of the ELISA technique. One sample was non reactive by 
PCR and by OraQuick on sputum and serum but positive by 
triple ELISAs. This may be due to the detection of different 
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analytes by PCR and ELISA and/or due to a false positive 
ELISA result. A Western Blot test might help resolve this 
issue. 
  In a pilot study, on a limited number of samples, we 
reported a good diagnostic accuracy of the Oraquick test 
on sputum samples, and had stressed the need to test a 
larger cohort in Central India[5]. A study from South India[6], 
however, reported an inadequate performance on sputum 
among a low HIV prevalence population. A study from 
Botswana, reported a sensitivity of 97.1% and specificity of 
98.3% on initial sputum specimens[3]. This study had been 
carried out on a much larger cohort (377 patients) in an area 
with a very high prevalence of HIV infection (84% of the 
cohort were HIV positive by serum ELISA). 
  Our study found an HIV prevalence of 2.83% in contrast 
to the 0.11% prevalence in our region[7]. Our hospital based 
estimate is obviously higher because it is a selected sample 
of suspects with TB/HIV co-infection. 
  Community based estimates are urgently needed to 
determine the performance of OraQuick for screening HIV 
infection in TB patients, particularly in view of the recent 
report of  false positive results occurring in a performance 
study of OraQuick oral-fluid rapid HIV tests in Minnesota[8]. 
Another study had reduced specificity in stored sputum 
samples[9]. 
  This testing method may be useful for conducting HIV 
surveillance in possible co-infected TB patients on sputum 
specimens collected as a part of the RNTCP. Since there 
is no investment on infrastructure, it may be possible 
for paramedical health professionals to carry it out at 
Microscopy Centres on sputum samples, particularly in areas 
with low HIV endemicity. 
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